Biogen Inc. (BIIB)

273.24 +0.36 (+0.13%) At close: 4:00PM EST

Biogen Inc.

225 Binney Street
Cambridge, MA 02142
United States
617 679 2000
http://www.biogen.com

Sector(s): Healthcare
Industry: Drug Manufacturers—General
Full Time Employees: 9,100

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Michel Vounatsos	CEO & Director	5.72M	N/A	1962
Ms. Susan H. Alexander	Exec. VP, Chief Legal Officer & Sec.	1.99M	1.77M	1957
Dr. Alfred W. Sandrock Jr.	Exec. VP of R&D	1.87M	N/A	1958
Mr. Chirfi Guindo	Exec. VP of Global Product Strategy & Commercialization	1.32M	N/A	1966
Mr. Michael R. McDonnell	Exec. VP & CFO	N/A	N/A	1964
Ms. Robin C. Kramer	Sr. VP & Chief Accounting Officer	N/A	N/A	1966
Mr. Mark J. Hernon	Sr. VP & Chief Information Officer	N/A	N/A	1964
Ms. Natacha Gassenbach	Chief Communication Officer & Head of Corp. Affairs	N/A	N/A	N/A
Dr. Ginger Gregory	Exec. VP & Chief HR Officer	N/A	N/A	1968
Dr. Alphonse Galdes	Exec. VP of Pharmaceutical Operations & Technology	N/A	N/A	1953

Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; and Ionis Pharmaceuticals, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Biogen Inc.’s ISS Governance QualityScore as of December 2, 2020 is 4. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 2; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.